Trial Profile
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Mar 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Relatlimab (Primary)
- Indications Basal cell cancer
- Focus Therapeutic Use
- 15 Mar 2023 Planned number of patients changed from 40 to 57.
- 13 Mar 2023 Planned End Date changed from 1 Nov 2026 to 1 Nov 2027.
- 13 Mar 2023 Planned primary completion date changed from 1 Nov 2023 to 1 Nov 2024.